SubRed Therapeutics

SubRed Therapeutics is a biotechnology company specializing in the development of site-directed RNA editing therapies to treat genetic diseases. Spun out from the University of Tübingen, the company utilizes its proprietary SubRed platform to recruit endogenous Adenosine Deaminase Acting on RNA (ADAR) enzymes for precise adenosine-to-inosine (A-to-I) conversions in target mRNA. This approach allows for the correction of pathogenic mutations or the modulation of protein function without the permanent genomic changes associated with DNA editing. By leveraging the cell's natural machinery through synthetic recruitment oligonucleotides, SubRed aims to provide a safer and more controllable therapeutic modality. The company is currently in the pre-clinical stage, focusing on optimizing its platform for various high-unmet-need indications. SubRed is backed by prominent life science investors, including Forbion, to advance its pipeline of RNA-based medicines.